AbbVie gains on European approvals
AbbVie rises on new drug approvals
ABBV highs +1.6% after some approvals overnight in Europe (AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia AreataMost; AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer)